N6-methyladenosine Modified LINC00901 Promotes Pancreatic Cancer Progression Through IGF2BP2/MYC Axis

Overview

Journal Genes Dis

Date 2023 May 24

PMID 37223505

Authors

Wan-Xin Peng

Fei Liu

Jia-Hong Jiang

Hang Yuan

Ziqiang Zhang

Liu Yang

Yin-Yuan Mo

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence indicates that RNA methylation at N-methyladenosine (m6A) plays an important regulatory role in gene expression and aberrant mRNA m6A modification is often associated with a variety of cancers. However, little is known whether and how m6A-modification impacts long non-coding RNA (lncRNA) and lncRNA-mediated tumorigenesis, particularly in pancreatic ductal adenocarcinoma (PDAC). In the present study, we report that a previously uncharacterized lncRNA, LINC00901, promotes pancreatic cancer cell growth and invasion and moreover, LINC00901 is subject to m6A modification which regulates its expression. In this regard, YTHDF1 serves as a reader for the m6A modified LINC00901 and downregulates the LINC00901 level. Notably, two conserved m6A sites in LINC00901 are critical to the recognition of LINC00901 by YTHDF1. Finally, RNA sequencing (RNA-seq) and gene function analysis revealed that LINC00901 positively regulates MYC through upregulation of IGF2BP2, a known RNA binding protein that can enhance MYC mRNA stability. Together, our results suggest that there is a LINC00901-IGF2BP2-MYC axis through which LINC00901 promotes PDAC progression in an m6A dependent manner.

Citing Articles

The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.

Xie X, Fang Z, Zhang H, Wang Z, Li J, Jia Y EXCLI J. 2025; 24:113-150.

PMID: 39967906 PMC: 11830918. DOI: 10.17179/excli2024-7935.

Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review).

Shen J, Ding Y Mol Med Rep. 2025; 31(3).

PMID: 39886962 PMC: 11795254. DOI: 10.3892/mmr.2025.13441.

Novel insights into the interaction between IGF2BPs and ncRNAs in cancers.

Sun Y, Wu J, Sun W, Liu C, Shi X Cancer Cell Int. 2024; 24(1):437.

PMID: 39732659 PMC: 11682635. DOI: 10.1186/s12935-024-03591-z.

Non-coding RNA-Mediated N6-Methyladenosine (mA) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response.

Hashemi M, Daneii P, Zandieh M, Raesi R, Zahmatkesh N, Bayat M Noncoding RNA Res. 2023; 9(1):84-104.

PMID: 38075202 PMC: 10700483. DOI: 10.1016/j.ncrna.2023.11.005.

Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.

Zhang F, Zhang R, Zong J, Hou Y, Zhou M, Yan Z Front Immunol. 2023; 14:1279789.

PMID: 37928532 PMC: 10620970. DOI: 10.3389/fimmu.2023.1279789.

References

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

Hung C, Wang L, Yu Y, Chen H, Srivastava S, Petrovics G . A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014; 111(52):18697-702. PMC: 4284533. DOI: 10.1073/pnas.1415669112. View

Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo Y . MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene. 2010; 30(7):822-31. DOI: 10.1038/onc.2010.463. View

Li N, Hui H, Bray B, Gonzalez G, Zeller M, Anderson K . METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. Cell Rep. 2021; 35(6):109091. PMC: 8090989. DOI: 10.1016/j.celrep.2021.109091. View

Wang S, Chai P, Jia R, Jia R . Novel insights on mA RNA methylation in tumorigenesis: a double-edged sword. Mol Cancer. 2018; 17(1):101. PMC: 6054842. DOI: 10.1186/s12943-018-0847-4. View

Roundtree I, He C . Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Trends Genet. 2016; 32(6):320-321. DOI: 10.1016/j.tig.2016.03.006. View

Liu J, Harada B, He C . Regulation of Gene Expression by N-methyladenosine in Cancer. Trends Cell Biol. 2019; 29(6):487-499. PMC: 6527461. DOI: 10.1016/j.tcb.2019.02.008. View

Wang X, Lu Z, Gomez A, Hon G, Yue Y, Han D . N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2013; 505(7481):117-20. PMC: 3877715. DOI: 10.1038/nature12730. View

Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z . LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 2013; 41(9):4976-87. PMC: 3643595. DOI: 10.1093/nar/gkt182. View

10.

Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z . -Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression. Cancer Res. 2020; 81(4):923-934. DOI: 10.1158/0008-5472.CAN-20-1619. View

11.

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View

12.

Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y . lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell. 2018; 33(4):706-720.e9. PMC: 6143179. DOI: 10.1016/j.ccell.2018.03.006. View

13.

Wang X, Zhao B, Roundtree I, Lu Z, Han D, Ma H . N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015; 161(6):1388-99. PMC: 4825696. DOI: 10.1016/j.cell.2015.05.014. View

14.

Wu F, Chiocca S, Beck W, Mo Y . Gam1-associated alterations of drug responsiveness through activation of apoptosis. Mol Cancer Ther. 2007; 6(6):1823-30. DOI: 10.1158/1535-7163.MCT-06-0771. View

15.

Leppek K, Stoecklin G . An optimized streptavidin-binding RNA aptamer for purification of ribonucleoprotein complexes identifies novel ARE-binding proteins. Nucleic Acids Res. 2013; 42(2):e13. PMC: 3902943. DOI: 10.1093/nar/gkt956. View

16.

Zhang J, Bai R, Li M, Ye H, Wu C, Wang C . Excessive miR-25-3p maturation via N-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019; 10(1):1858. PMC: 6478927. DOI: 10.1038/s41467-019-09712-x. View

17.

Huisman B, Manske G, Carney S, Kalantry S . Functional Dissection of the m6A RNA Modification. Trends Biochem Sci. 2017; 42(2):85-86. PMC: 5272839. DOI: 10.1016/j.tibs.2016.12.004. View

18.

Yang Y, Hsu P, Chen Y, Yang Y . Dynamic transcriptomic mA decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018; 28(6):616-624. PMC: 5993786. DOI: 10.1038/s41422-018-0040-8. View

19.

Roundtree I, Luo G, Zhang Z, Wang X, Zhou T, Cui Y . YTHDC1 mediates nuclear export of N-methyladenosine methylated mRNAs. Elife. 2017; 6. PMC: 5648532. DOI: 10.7554/eLife.31311. View

20.

Peng W, He R, Zhang Z, Yang L, Mo Y . LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription. Oncogene. 2019; 38(41):6770-6780. DOI: 10.1038/s41388-019-0918-z. View